UroLift® 2 Implant Cartridge Carton
The UroLift® 2 Cartridge (UL2-C) box contains four (4) UroLift® 2 Implant Cartridges, in individual, sterile, sealed packages.
The UroLift® 2 System is the next-generation of the minimally invasive Prostatic Urethral Lift procedure to treat symptoms of an enlarged prostate secondary to benign prostatic hyperplasia (BPH). The UroLift® 2 System delivers the UroLift® Implant to provide an option for patients looking for an alternative to medications or major surgery. It is the only leading transurethral BPH treatment that does not require heating, cutting, or removal of prostate tissue.*
The UroLift® 2 System is comprised of two main components: the UroLift® 2 Delivery Handle and the UroLift® 2 Implant Cartridge. Each UroLift® 2 Implant Cartridge comes pre-loaded with the components of one UroLift® Implant. Typically one UroLift® Delivery Handle is used per procedure.
The UroLift® 2 Delivery Handle is only sold in the UroLift® 2 Cartridge Handle Kit (UL2-CHK).
*Roehrborn, J Urol 2013; AUA Guidelines 2003, 2020; Mirakhur, Can Assoc Rad J 2017; McVary, J Urol 20156; Gilling, Can J Urol 2020
As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.
Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.
INDICATIONS FOR USE
In the United States, the UroLift® 2 System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia, in men 45 years of age or older.
CONTRAINDICATIONS
In the United States, the UroLift® 2 System should not be used if the patient has:
• Prostate volume of >100 cc
• A urinary tract infection
• Urethral conditions that may prevent insertion of delivery system into bladder
• Urinary incontinence due to incompetent sphincter
• Current gross hematuria
MAC02527-02 Rev.A